Trial reportFrontiers in nutrition2026
Effect of long-term intake of
Trial report in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objectives: Coping strategies for menstruation-related symptoms are required to support women's health-related quality of life (QoL) and the continued social advancement of women. Previous studies have reported that short-term intake of Methods: A randomized, double-blind, placebo-controlled study was conducted. Participants were 140 healthy women aged 20-39 years and were randomly assigned to receive aLA (900 mg/day) or placebo for three menstrual cycles. Premenstrual and intramenstrual symptoms were assessed at each cycle. The primary outcome was subjective symptoms on the Menstrual Distress Questionnaire (MDQ), and secondary outcomes were the 36-Item Short Form Health Survey (SF-36), subjective symptoms on the Visual Analog Scale, and urinary prostaglandins. Results: The primary outcome, the MDQ, showed no significant differences in the total score or the six factor scores between groups, either premenstrually or during menstruation. In exploratory analyses, aLA intake significantly alleviated the premenstrual MDQ sub-scores "Weight gain" and "Lowered motor coordination" compared with placebo ( Conclusion: In this trial, long-term aLA supplementation did not improve overall menstruation-related symptoms as assessed by the primary outcome. However, secondary outcomes indicated potential benefits in role-related and social aspects of premenstrual QoL. These findings are exploratory, requiring further studies for confirmation. Clinical trial registration: https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000063507, UMIN-CTR UMIN000055576.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.